Paclitaxel-Coated Devices in the Treatment of Femoropopliteal Stenosis among patients ≥65 years old: An ACC PVI Registry Analysis.

[1]  J. Ioannidis,et al.  Mortality and Paclitaxel-Coated Devices , 2020, Circulation.

[2]  Daniel J. Bertges,et al.  Mortality After Paclitaxel Coated Balloon Angioplasty and Stenting of Superficial Femoral and Popliteal Artery in the Vascular Quality Initiative , 2020, Circulation. Cardiovascular interventions.

[3]  M. Schermerhorn,et al.  Long Term Survival after Femoropopliteal Artery Revascularisation with Paclitaxel Coated Devices: A Propensity Score Matched Cohort Analysis. , 2020, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.

[4]  M. Shishehbor,et al.  Paclitaxel-coated peripheral artery devices are not associated with increased mortality. , 2019, Journal of vascular surgery.

[5]  S. Kaul,et al.  Bayes Factor Meta-Analysis of the Mortality Claim for Peripheral Paclitaxel-Eluting Devices. , 2019, JACC. Cardiovascular interventions.

[6]  B. Hammill,et al.  Use and 1-year outcomes with conventional and drug-coated balloon angioplasty in patients with lower extremity peripheral artery disease. , 2019, American heart journal.

[7]  J. Beckman,et al.  Paclitaxel-Coated Balloons and Eluting Stents: Is There a Mortality Risk in Patients with Peripheral Artery Disease? , 2019, Circulation.

[8]  J. Gerss,et al.  Mortality after use of paclitaxel-based devices in peripheral arteries: a real-world safety analysis , 2019, European heart journal.

[9]  E. Ducasse,et al.  Systematic review and updated meta-analysis of the use of drug-coated balloon angioplasty versus plain old balloon angioplasty for femoropopliteal arterial disease. , 2019, Journal of vascular surgery.

[10]  M. Jaff,et al.  Expanding opportunities to understand quality and outcomes of peripheral vascular interventions: The ACC NCDR PVI Registry. , 2019, American heart journal.

[11]  J. Beckman,et al.  Association of Survival With Femoropopliteal Artery Revascularization With Drug-Coated Devices , 2019, JAMA cardiology.

[12]  R. Virmani,et al.  Comparison of Biologic Effect and Particulate Embolization after Femoral Artery Treatment with Three Drug-Coated Balloons in Healthy Swine Model. , 2019, Journal of vascular and interventional radiology : JVIR.

[13]  M. Makaroun,et al.  Nationwide trends in drug-coated balloon and drug-eluting stent utilization in the femoropopliteal arteries. , 2018, Journal of Vascular Surgery.

[14]  D. Scheinert,et al.  Drug-Coated Balloon Treatment for Femoropopliteal Artery Disease: The Chronic Total Occlusion Cohort in the IN.PACT Global Study. , 2017, JACC. Cardiovascular interventions.

[15]  Correction to: Durable Clinical Effectiveness With Paclitaxel-Eluting Stents in the Femoropopliteal Artery 5-Year Results of the Zilver PTX Randomized Trial. , 2019, Circulation.

[16]  S. Spiliopoulos,et al.  Risk of Death Following Application of Paclitaxel‐Coated Balloons and Stents in the Femoropopliteal Artery of the Leg: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials , 2018, Journal of the American Heart Association.

[17]  M. Dake,et al.  Durable Clinical Effectiveness With Paclitaxel-Eluting Stents in the Femoropopliteal Artery , 2016, Circulation.